This brand name is authorized in New Zealand
The drug NITRONOX contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Nitrous oxide (N2O)
UNII K50XQU1029 - NITROUS OXIDE
|
|
Nitrous oxide is a potent analgesic and a weak anaesthetic. Induction with nitrous oxide is relatively rapid, but a concentration of about 70% is needed to produce unconsciousness. |
|
2
Oxygen
UNII S88TT14065 - OXYGEN
|
|
Oxygen is an essential element for living organisms. It is involved in cellular metabolism and catabolism and permits production of energy in the form of adenosine triphosphate (ATP). The variation of the partial pressure of oxygen in the blood affects the cardiovascular system, the respiratory system, cellular metabolism, and the central nervous system. Deprivation of oxygen, resulting in tissue hypoxia, results in a rapid deterioration of myocardial and central nervous activity. Intervention with oxygen therapy is essential for the resolution of adequate tissue oxygenation. |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 5348 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
